U.S. pharmaceutical giant Pfizer and German company BioNTech said on Wednesday that the co-developed vaccine against the new coronavir is 95% effective, according to the final results of the trials.
Studies have also shown that the vaccine is generally safe, according to both companies.
“At a time when hundreds of thousands of people are being infected on a global scale every day, we urgently need to deliver a safe and effective vaccine to the world,” said Albert Burla, head of Pfizer.
Last week, Pfizer and BioNTech announced that the vaccine they developed was 90% effective, according to preliminary research.
Regulatory approval is required before the vaccine can be used.
The European Commission (EC) has already announced on November 11 that it has reached an agreement with the US pharmaceutical giant Pfizer and the German company BioNTech for the supply of up to 300 million doses of the experimental Covid-19 vaccine.
Under the agreement, the EU-27 will be able to buy 200 million doses of vaccine and will be able to buy another 100 million doses.
The 27 EU Member States will receive doses according to their population.
The EU has already reached an agreement with AstraZeneca, Sanofi-GSK, Janssen Pharmaceutica and CureVac to purchase their Covid-19 vaccines when they are available and is in talks with Moderna.
The US company Moderna said on Monday that the Covid-19 vaccine it had developed was 94.5% effective in clinical trials.
–
